In recent years, the incidence of dry eye disease has continued to increase, significantly, impairing patients′ quality of life. Moisture chamber spectacles (MCS), a non-invasive physical therapy with a development history spanning several decades, have been introduced into the management of dry eye and other ocular surface diseases since the 1970s, and have undergone multiple generations of evolution from early simple moisture chamber structures to functionally optimized products. The core mechanism of MCS lies in creating a relatively enclosed and humid periocular environment, thereby reducing tear evaporation and protecting the ocular surface. As a result, MCS have attracted increasing attention in the management of dry eye disease, exposure keratitis, and postoperative ocular surface protection, and have been concurrently incorporated into several international and national guidelines and expert consensuses as a basic or additional therapeutic option for dry eye disease.